https://orcid.org/0000-0002-7874-4566
References
- Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College. Circulation. 2010 June.
- Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016 November.
- Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011 February.
- Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017.
- Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and patients with and without diabetes mellitus. Am J Cardiol. 2003:1362-1365.
- Ferreira IA, Eybrechts KL, Mocking AIM, et al. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004.
- Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association; 1995:1114-1120.
- Russo I, Viretto M, Barale C, et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes J. 2012 November.
- Gravinese C, Bianco M, Cerrato E, et al. Is aspirin still the cornerstone of antiplatelet therapy in patients with coronary artery disease? A historical and practical narrative review. 2017:94-101.
- Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 December.
- Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004:784-794.
- Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019 January. 2018:S86-S104.
- Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American diabetes association. Diabetes Care. 2015 September.
- Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016:836-845.
- ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-1539. doi: 10.1056/NEJMoa1804988.
- Xing Y, Tan KCB. Aspirin for primary prevention of cardiovascular disease in diabetes. J Diabetes Investig. 2019.
- McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018:1509-1518.
- Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial. The Lancet. 2018:1036-1046.
- Richman IB, Owens DK. Aspirin for primary prevention. Medical Clinics of North America; 2017;101(4):713-724. doi:10.1016/j.mcna.2017.03.004.
- Ogawa H, Nakayama M, Morimoto T, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Erratum in: JAMA. 2009 May 13;301(18):1882. JAMA. 2012 Nov 14;308(18):1861.